Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Activation of the human epidermal growth factor receptor 1 (HER1) in prostate cancer contributes to metastatic progression as well as to disease relapse. Here, we determined the toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Caballero, Iraida, Aira, Lazaro E., Lavastida, Anabel, Popa, Xitlally, Rivero, Javier, González, Joaquín, Mesa, Mónica, González, Narjara, Coba, Kelly, Lorenzo-Luaces, Patricia, Wilkinson, Barbara, Santiesteban, Yuliannis, Santiesteban, Yanela, Troche, Mayelin, Suarez, Eduardo, Crombet, Tania, Sánchez, Belinda, Casacó, Angel, Macías, Amparo, Mazorra, Zaima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423955/
https://www.ncbi.nlm.nih.gov/pubmed/28539888
http://dx.doi.org/10.3389/fphar.2017.00263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423955/
https://www.ncbi.nlm.nih.gov/pubmed/28539888
http://dx.doi.org/10.3389/fphar.2017.00263

Ejemplares similares